From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
Characteristic | All Cases (N = 1,115) | Cases with Clinical Data (N = 967) | All Controls (N = 710) |
---|---|---|---|
Age1 | Â | Â | Â |
Mean ± SD | 48.6 ± 9.0 | 48.9 ± 9.2 | 48.5 ± 9.1 |
Menopausal Status2 | Â | Â | Â |
Pre- | 828 (75.0%) | 710 (73.7%) | 497 (70.2%) |
Post- | 276 (25.0%) | 253 (26.3%) | 211 (29.8%) |
Ethnicity | Â | Â | Â |
White | 1062 (95.3%) | 899 (93.0%) | 653 (95.2%) |
Non-White | 53 (4.7%) | 68 (7.0%) | 33 (4.8%) |
Parity | Â | Â | Â |
Nulliparous | 201 (19.5%) | 204 (21.5%) | 106 (15.0%) |
1–2 child | 620 (60.2%) | 562 (59.2%) | 434 (61.2%) |
> 3 children | 209 (20.3%) | 183 (19.3%) | 168 (23.8%) |
First-degree Family History3 | Â | Â | Â |
No | 731 (65.6%) | 618 (63.9%) | 641 (90.3%) |
Yes | 384 (34.4%) | 349 (36.1%) | 69 (9.7%) |
OFBCR Defined Genetic Risk Case4 | Â | Â | Â |
No | 311 (27.9%) | 281 (29.1%) | NA |
Yes | 804 (72.1%) | 686 (70.9%) | Â |
Histology | Â | Â | Â |
Infiltrating Ductal No Special Type | -- | 824 (90.2%) | NA |
Lobular | Â | 65 (7.1%) | Â |
Other Special Type5 | Â | 25 (2.7%) | Â |
T Stage | Â | Â | Â |
pT1 (<2 cm) | -- | 607 (64.0%) | NA |
pT2 (2–5 cm) |  | 281 (29.6%) |  |
pT3/pT4 (>5 cm) | Â | 34 (3.6%) | Â |
pTx (not accessible) | Â | 26 (2.7%) | Â |
# Positive Lymph Nodes | Â | Â | Â |
None | -- | 538 (56.6%) | NA |
1–3 |  | 243 (25.6%) |  |
≥4 |  | 113 (11.9%) |  |
Nx (not accessible) | Â | 56 (5.9%) | Â |
Grade | Â | Â | Â |
I (well differentiated) | -- | 194 (21.5%) | NA |
II (moderately differentiated) | Â | 351 (38.8%) | Â |
III (poorly differentiated) | Â | 359 (39.7%) | Â |
Lymphatic Vessel Invasion | Â | Â | Â |
Negative | -- | 582 (66.1%) | NA |
Positive | Â | 299 (33.9%) | Â |
Estrogen Receptor Status | Â | Â | Â |
Negative | -- | 230 (24.5%) | NA |
Equivocal | Â | 49 (5.2%) | Â |
Positive | Â | 659 (70.3%) | Â |
Progesterone Receptor Status | Â | Â | Â |
Negative | -- | 259 (27.8%) | NA |
Equivocal | Â | 55 (5.9%) | Â |
Positive | Â | 618 (66.3%) | Â |